​

GT Biopharma (GTBP) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

GTBP Stock Rating

GT Biopharma stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

GTBP Price Target Upside V Benchmarks

TypeNameUpside
StockGT Biopharma-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.46$0.46$0.46
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-1---1
Feb, 26-1---1
Jan, 26-1---1
Dec, 25-1---1
Nov, 25-1---1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 04, 2023EF HuttonHoldinitialise
Sep 13, 2022H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-30 $-24 $-18 $-12 $-6 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-5.64$-6.94$-6.68--
Avg Forecast$-0.30$-6.79$-2.11$-27.30$-23.10
High Forecast$-0.30$-6.79$-2.11$-27.30$-23.10
Low Forecast$-0.30$-6.79$-2.11$-27.30$-23.10
Surprise %1780.00%2.21%216.59%--

Revenue Forecast

$5M $18M $31M $44M $57M $70M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-----
Avg Forecast-$13.00M$13.50M$9.70M$67.70M
High Forecast-$13.00M$13.50M$9.70M$67.70M
Low Forecast-$13.00M$13.50M$9.70M$67.70M
Surprise %-----

Net Income Forecast

$-40M $-32M $-24M $-16M $-8M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-7.60M$-13.16M$-34.45M--
Avg Forecast$-404.31K$-9.15M$-2.84M$-36.79M$-31.13M
High Forecast$-404.31K$-9.15M$-2.84M$-36.79M$-31.13M
Low Forecast$-404.31K$-9.15M$-2.84M$-36.79M$-31.13M
Surprise %1778.99%43.83%1111.42%--

GTBP Forecast FAQ

Is GT Biopharma stock a buy?

GT Biopharma stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that GT Biopharma is a favorable investment for most analysts.

What is GT Biopharma's price target?

GT Biopharma's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $0.46.

How does GT Biopharma stock forecast compare to its benchmarks?

GT Biopharma's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for GT Biopharma over the past three months?

  • March 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is GT Biopharma’s EPS forecast?

GT Biopharma's average annual EPS forecast for its fiscal year ending in December 2026 is $-27.3, marking a 308.68% increase from the reported $-6.68 in 2025. Estimates for the following years are.

What is GT Biopharma’s revenue forecast?

GT Biopharma's average annual revenue forecast for its fiscal year ending in December 2026 is $9.7M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for.

What is GT Biopharma’s net income forecast?

GT Biopharma's net income forecast for the fiscal year ending in December 2026 stands at $-36.793M, representing an 6.80% increase from the reported $-34.449M in 2025. Projections indicate .